Leg Veins: Why Spider Veins Are Usually a Symptom Rather Than the Problem, Why the Ultrasound Belongs Before the Needle, and Why the Ones That Come Back Were Never Treated at the Source

The complaint arrives in summer. A patch of fine blue and red lines has appeared on the outer thigh, or a cluster has spread across the ankle, and the patient has decided to stop wearing certain clothes. They book a consultation somewhere that advertises spider vein removal, they are quoted a per-session price, and in many clinics the first injection happens that same afternoon. It works. The lines fade over a few weeks. Eighteen months later the same patch is back, sometimes with more vessels than before, and the patient concludes that leg veins simply cannot be fixed.

Often the veins were treated correctly and simply recurred, because this is a progressive condition and nothing on the market stops it. But in a meaningful share of these cases something else happened: the visible vessels were the runoff from a failed valve much higher up the leg, nobody looked for it, and injecting the surface was always going to be an exercise in emptying a sink with the tap running. The step that distinguishes those two situations takes about twenty minutes and involves an ultrasound probe. It is the most informative thing in this entire field, and it is the step most often skipped in the cosmetic setting.

What the veins are actually doing, and what it means when they fail

The short answer: leg veins move blood upward against gravity using one-way valves and the squeeze of the calf muscles; when a valve stops closing properly the blood falls back down, a process called reflux, and the pressure it creates at the bottom of the leg is what produces bulging varicose veins, reticular veins, and the fine telangiectasias that patients call spider veins; and reflux is formally defined on ultrasound as retrograde flow lasting longer than half a second in a superficial vein.

The system has two halves. The deep veins sit inside the muscle compartments and carry the great majority of the blood back to the heart. The superficial veins, principally the great saphenous running up the inner leg and the small saphenous running up the back of the calf, sit in a compartment just under the skin. Perforating veins connect the two, and every one of these vessels contains delicate valves that are supposed to permit flow in one direction only. Walking compresses the calf, the calf squeezes the deep veins, the valves shut behind the moving column of blood, and the leg empties upward. That is the pump.

When valves in the superficial system fail, the blood column is no longer broken into segments. A standing patient then has an uninterrupted vertical column of blood pressing down on the smallest vessels at the bottom, and those vessels dilate. The clinical vocabulary follows size. Telangiectasias, the spider veins, are under about one millimeter. Reticular veins, the flat blue-green network that often feeds them, run about one to three millimeters. Varicose veins are three millimeters or larger and bulge above the skin. Clinicians classify all of it with the CEAP system, where C1 is spider and reticular veins, C2 is varicose veins, C3 is swelling, C4 is skin discoloration and thickening, and C5 and C6 are healed and open ulcers. Those letters are worth knowing, because they are the language insurance uses.

This is common to the point of being unremarkable. The Edinburgh Vein Study, one of the more rigorously sampled population surveys in the field, found visible telangiectasias or reticular veins in the large majority of the adults it screened, and trunk varicose veins in roughly a third. Risk rises with age, with pregnancy, with family history, with prolonged standing occupations, and with higher body weight. A twenty-eight-year-old with a few thigh vessels has an extremely common finding, not a disease.

"Spider veins are a size category, not a diagnosis. The question that decides your treatment is not how the vessels look but whether there is a failed valve above them feeding pressure downward, and that question is answered by an ultrasound rather than by a glance at your leg."

The scan that decides the entire plan

The short answer: duplex ultrasound performed with the patient standing, not lying down, is the standard evaluation for leg veins, and both the Society for Vascular Surgery and the American Venous Forum place it at the front of the diagnostic pathway; it identifies whether the great saphenous, small saphenous, or perforating veins are refluxing; and treating surface vessels fed by an untreated refluxing trunk is the most reliable way to produce a recurrence.

The examination is not complicated. The patient stands, the technologist compresses and releases the calf or has the patient bear down, and the probe watches which way the blood moves as the muscle relaxes. Flow that reverses and keeps reversing for more than half a second in a superficial vein is reflux. The scan maps where it starts, most often at the saphenofemoral junction in the groin or the saphenopopliteal junction behind the knee, and follows it down the leg. It also confirms that the deep system is open and competent, which matters enormously, because superficial veins in a leg with chronic deep obstruction may be carrying blood that has nowhere else to go, and closing them is the wrong move.

Performed lying down, the study is close to worthless, because the hydrostatic column that produces the reflux is gone. A patient who is scanned supine, briefly, on the same table where the injections are about to happen has not really been scanned.

Not every patient needs one. An otherwise asymptomatic person with a small isolated patch of telangiectasias, no bulging veins, no aching, no swelling, and no family history of venous ulcers is a reasonable candidate for direct treatment of the surface vessels. The threshold for scanning should drop sharply in the presence of any of the following: visible bulging veins anywhere on the leg, aching or heaviness that worsens through the day, ankle swelling, brown discoloration around the ankle, restless or itching legs at night, a previous deep vein thrombosis, or spider veins that have already been treated once and returned. That last item deserves emphasis. Recurrence after an apparently successful session is the classic history of untreated axial reflux.

There is a second source worth naming, because it is missed constantly. Veins that appear on the vulva, the buttock, or the back of the upper thigh, particularly in a woman who has been pregnant, can be fed by refluxing pelvic veins rather than by the saphenous system. Chasing them from below produces exactly the frustrating cycle described at the top of this piece. The evaluation for that is different and belongs to an interventional radiologist or a vascular specialist.

Sclerotherapy: what the injection does, and what it can leave behind

The short answer: sclerotherapy injects a detergent solution that strips the lining of the vein, causing it to seal shut and be reabsorbed; polidocanol and sodium tetradecyl sulfate are the agents approved by the Food and Drug Administration for this use in the United States; it remains the reference treatment for vessels under about three millimeters; and its two characteristic cosmetic side effects, brown staining and telangiectatic matting, are common enough that they belong in every consent conversation.

Most patients need more than one session. Published practice and manufacturer guidance both point toward a course rather than an event, typically two to four sessions spaced several weeks apart for a given area, with the treated vessels fading over one to three months rather than disappearing at the appointment. A clinic quoting a single session for a whole leg is quoting optimistically. The piece on what a cosmetic quote actually covers applies directly here, because per-session pricing and per-course pricing are very different numbers.

Two side effects define the patient experience. The first is hyperpigmentation: a brown line along the track of the treated vessel, caused by hemosiderin, the iron pigment left behind when trapped blood breaks down. It is reported in a substantial minority of patients, most often fades over six to twelve months, and in a small percentage persists beyond a year. Drainage of trapped clot a few weeks after treatment reduces it. The second is telangiectatic matting, a blush of new fine vessels appearing where none were before, generally in the weeks after treatment, which is unpredictable, more common with higher concentrations and larger volumes, and usually but not always self-resolving.

Both of these sit differently on different skin. Post-inflammatory hyperpigmentation is more likely and more persistent on deeper skin tones, for the reasons set out in the piece on cosmetic procedures on deeper skin tones, and a patient with a Fitzpatrick type IV to VI leg should hear an explicit plan for test-spotting and for lower concentrations rather than a blanket reassurance.

The serious risks are rare and worth stating plainly. Injection into or adjacent to a small artery, classically near the inner ankle, can cause skin necrosis. Foam sclerotherapy has been associated with transient visual disturbance and migraine in a small percentage of patients, attributed to gas bubbles crossing a patent foramen ovale, and with rare case reports of more serious neurological events. Deep vein thrombosis after sclerotherapy is uncommon but documented, which is why the piece on clot risk after cosmetic procedures is relevant to what many patients think of as a lunchtime appointment.

Closing the source: what replaced vein stripping

The short answer: when duplex shows a refluxing saphenous trunk, the modern treatment closes that vein from the inside using heat, chemical foam, or adhesive, performed under local anesthesia in an office with the patient walking out afterward; endovenous laser ablation and radiofrequency ablation have largely replaced open surgical stripping; and published closure rates for thermal ablation sit in the region of ninety percent or better at five years.

Thermal ablation works by threading a catheter into the vein under ultrasound guidance and delivering laser or radiofrequency energy along its length while withdrawing it. The vein contracts, seals, and is gradually absorbed. Tumescent local anesthetic is infiltrated around the vein first, which both numbs it and insulates the surrounding tissue from the heat. The whole thing takes under an hour and the patient walks immediately, which is specifically encouraged.

The non-thermal options exist largely to avoid the tumescent step. Mechanochemical ablation combines a rotating wire with a liquid sclerosant. Cyanoacrylate closure, marketed as VenaSeal and approved by the Food and Drug Administration in 2015, glues the vein shut and requires no tumescent infiltration and, in most protocols, no compression stockings afterward. Polidocanol injectable foam, approved in 2013, treats the great saphenous system chemically. Each has trade-offs, and patients should be aware that the branded names attached to these technologies are trade names rather than indicators of quality, a distinction covered in the piece on trademarked procedure names.

The United Kingdom's National Institute for Health and Care Excellence guidance on varicose veins has for over a decade recommended endothermal ablation as the first-line treatment for confirmed truncal reflux, with foam sclerotherapy next and open surgery last, which is a reasonable summary of where the evidence has settled internationally. Bulging tributary veins that remain after the trunk is closed are removed through needle-sized incisions in a procedure called ambulatory phlebectomy, often at the same visit.

Recurrence remains the honest caveat. Even after technically successful closure, a meaningful proportion of patients develop new visible veins over five to ten years, through progression of the underlying condition and through new vessel growth near the treated junction. Treating the source changes the odds substantially. It does not confer immunity, and anyone promising a permanent answer is overselling.

Surface lasers, compression, and the claims that run ahead of the evidence

The short answer: long-pulsed 1064 nanometer Nd:YAG and related vascular lasers can clear very fine leg telangiectasias and are useful for vessels too small to cannulate, for needle-averse patients, and for matting left behind by injections; for most leg vessels above roughly half a millimeter, sclerotherapy still produces better clearance in fewer sessions; and graduated compression stockings manage symptoms and support healing but do not make existing veins disappear.

Leg veins are harder for lasers than facial vessels. They sit deeper, carry more deoxygenated blood, and face higher hydrostatic pressure, which is why the transfer of enthusiasm from facial redness treatment to the legs has generally disappointed. The reasonable role for surface laser on the leg is narrow and real: tiny residual vessels, matting, and patients who will not accept needles. A clinic presenting laser as a wholesale replacement for injections on the legs is describing a marketing position rather than a clinical one, in the same way that the piece on energy-based skin tightening describes for the face and body.

Compression deserves an honest framing too. Graduated stockings, typically in the twenty to thirty millimeter of mercury range, reliably reduce aching, heaviness, and swelling, and they are central to managing skin changes and preventing ulcer recurrence. They are frequently required by insurers as a documented trial of conservative therapy, commonly for six to twelve weeks, before an ablation will be authorized. What they do not do is remove veins that already exist. Evidence on compression after sclerotherapy is mixed, with some trials showing modest benefit for staining and clearance over one to three weeks, which is why protocols differ between clinics without either being wrong. The piece on the compression garment evidence makes the same point for body contouring.

One practical note on coverage: symptomatic varicose veins with documented reflux are a medical problem and are frequently covered by insurance after conservative therapy fails. Spider veins with no symptoms and no reflux are cosmetic and are not. That distinction, not the cost of the device, is why the same leg can generate two wildly different price conversations at two different clinics. It is also why a scan is in a patient's financial interest as well as their clinical one.

The honest summary

Leg veins are the rare cosmetic complaint with a genuine diagnostic test attached, and the test is quick, inexpensive, and non-invasive. A standing duplex ultrasound tells you whether the vessels you dislike are an isolated surface finding or the visible end of a refluxing saphenous trunk, and the answer changes both the treatment and the price. Treating the surface while an untreated source feeds pressure downward is the most common reason patients describe injections that worked for a season and then failed.

If there is no reflux, sclerotherapy with polidocanol or sodium tetradecyl sulfate remains the reference treatment for vessels under about three millimeters, expected across two to four sessions per area, with results maturing over one to three months. Expect a realistic discussion of brown staining and of matting, and expect a specific plan for both if your skin tone is deeper. Lasers have a narrow but genuine role for the smallest vessels and for matting.

If there is reflux, the sequence runs the other way: close the source with thermal ablation, cyanoacrylate, or foam, remove bulging tributaries with phlebectomy, and treat the remaining spider veins last. Closure rates are high, walking begins the same day, and recurrence over five to ten years is still possible because the underlying condition is progressive.

Two things are worth refusing. The first is a treatment plan written before anyone has looked at your leg with an ultrasound probe while you are standing, particularly if you have bulging veins, aching, ankle swelling, or a patch of spider veins that has already been treated and come back. The second is any promise that this is permanent. Veins are a lifelong plumbing condition, treatment is maintenance rather than cure, and the clinic worth booking with is the one that says so in the first conversation.